成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

<rt id="ouzo3"><em id="ouzo3"></em></rt>
<rt id="ouzo3"></rt><rt id="ouzo3"><meter id="ouzo3"><menu id="ouzo3"></menu></meter></rt>
<button id="ouzo3"><input id="ouzo3"><strike id="ouzo3"></strike></input></button><tfoot id="ouzo3"></tfoot><i id="ouzo3"><delect id="ouzo3"><label id="ouzo3"></label></delect></i>
  • Eliglustat hemitartrate

    Eliglustat hemitartrate Struktur
    928659-70-5
    CAS-Nr.
    928659-70-5
    Englisch Name:
    Eliglustat hemitartrate
    Synonyma:
    GENZ112638;Eligluhemitartrate;Eliglustat (Tartrate);Eliglustat (hemitartrate);Eliglustat tartrate (Genz-112638);GENZ-112638;GENZ 112638;GENZ112638;Eliglustat hemitartrate(Genz-99067);Eliglustat hemitartrate (Genz-112638);Eliglustat (Tartrate),Eliglustat tartrate;Genz112638,Inhibitor,Eliglustat,Genz 112638,inhibit,Eliglustat hemitartrate
    CBNumber:
    CB22667944
    Summenformel:
    C50H78N4O14
    Molgewicht:
    959.17272
    MOL-Datei:
    928659-70-5.mol

    Eliglustat hemitartrate Eigenschaften

    Schmelzpunkt:
    >133°C (dec.)
    storage temp. 
    -20°C Freezer, Under inert atmosphere
    L?slichkeit
    DMSO (Slightly), Methanol (Slightly)
    Aggregatzustand
    Solid
    Farbe
    White
    InChIKey
    KUBARPMUNHKBIQ-VTHUDJRQSA-N

    Sicherheit

    Eliglustat hemitartrate Chemische Eigenschaften,Einsatz,Produktion Methoden

    Beschreibung

    Eliglustat tartrate, developed and marketed by Genzyme Corporation (a subsidiary of Sanofi), was approved by the US FDA in August 2014 for the treatment of nonneuropathic (type 1) Gaucher disease (GD1) in both treatment-naive and treatment-experienced adult patients. It is the first oral treatment to be approved for first-line use in patients with Gaucher disease type 1, which is a rare lysosomal storage disease characterized by accumulation of lipid glucosylceramide (GL-1) due to insufficient production of the enzyme glucosylceramidase. Clinical complications include hepatosplenomegaly, anemia, thrombocytopenia, and bone involvement. Eliglustat is a specific inhibitor of glucosylceramide synthase with an IC50 of 10 ng/mL and acts as substrate reduction therapy for GD1; it has demonstrated non-inferiority to enzyme replacement therapy, which is the current standard of care, in Phase III trials.

    Verwenden

    Eliglustat Tartrate functions as an oral agent for treatment of Gaucher disease type 1, and lysosomal storage disorders in human. It also inhibits UDP-glucosylceramide synthase in mice thereby preventing Gaucher disease-associated with B-cell malignancy.

    Definition

    ChEBI: A tartrate that is the hemitartrate salt of eliglustat. A ceramide glucosyltransferase inhibitor used (as its tartrate salt) for treatment of Gaucher's disease.

    in vitro

    Eliglustat tartrate (Eliglustat hemitartrate) shows good potency with an IC50 of 24 nM and specificity against the target enzyme. Incubating K562 or B16/F10 cells for 72 h with increasing amounts of Genz-112638 (0.6-1000 nM) results in a dose-dependent reduction of both GM1 and GM3 cell surface levels. The mean IC50 value for inhibiting the cell surface presentation of GM1 in K562 cells was 24 nM (range 14-34 nM), and that for GM3 in B16/F10 cells was 29 nM (range 12-48 nM).

    Eliglustat hemitartrate Upstream-Materialien And Downstream Produkte

    Upstream-Materialien

    Downstream Produkte


    Eliglustat hemitartrate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

    Global( 100)Lieferanten
    Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
    ATK CHEMICAL COMPANY LIMITED
    +undefined-21-51877795
    ivan@atkchemical.com China 32956 60
    BOC Sciences
    +1-631-485-4226
    inquiry@bocsci.com United States 19553 58
    career henan chemical co
    +86-0371-86658258 +8613203830695
    factory@coreychem.com China 29810 58
    TargetMol Chemicals Inc.
    +1-781-999-5354 +1-00000000000
    marketing@targetmol.com United States 32161 58
    Shanxi Xuanran Import and Export Trade Co., Ltd.
    +8617735180244
    mike_yan@xuanranglobal.com CHINA 4017 58
    sgtlifesciences pvt ltd
    +8617013299288
    dj@sgtlifesciences.com China 12373 58
    InvivoChem
    +1-708-310-1919 +1-13798911105
    sales@invivochem.cn United States 6391 58
    Nantong HI-FUTURE Biology Co., Ltd.
    +undefined18051384581
    sales@chemhifuture.com China 3135 58
    TargetMol Chemicals Inc.

    support@targetmol.com United States 38631 58
    ShenZhen Trendseen Biological Technology Co.,Ltd.
    13417589054
    trendseenbio@gmail.com China 11681 58

    928659-70-5()Verwandte Suche:


    • Eliglustat (Tartrate)
    • Eliglustat (hemitartrate)
    • Eliglustat hemitartrate(Genz-99067)
    • GENZ112638
    • (2R,3R)-2,3-Dihydroxysuccinic acid - N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide (1:2)
    • N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide,(2R,3R)-2,3-dihydroxybutanedioic Acid
    • Eliglustat hemitartrate (Genz-112638)
    • GENZ-99067;GENZ99067;GENZ 99067;GENZ-112638;GENZ112638;GENZ 112638;ELIGLUSTAT TARTRATE
    • Eliglustat tartrate (Genz-112638)
    • GENZ-112638;GENZ 112638;GENZ112638
    • Eliglustat (Tartrate),Eliglustat tartrate
    • Genz112638,Inhibitor,Eliglustat,Genz 112638,inhibit,Eliglustat hemitartrate
    • N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide ((2R,3R)-2,3-dihydroxysuccinate)(2:1)
    • Eligluhemitartrate
    • 928659-70-5
    • C50H78N4O14
    • 1
    Copyright 2019 ? ChemicalBook. All rights reserved